Insider Selling: Inari Medical, Inc. (NASDAQ:NARI) COO Sells $698,940.00 in Stock

Inari Medical, Inc. (NASDAQ:NARIGet Rating) COO Andrew Hykes sold 9,000 shares of the business’s stock in a transaction dated Monday, November 21st. The shares were sold at an average price of $77.66, for a total value of $698,940.00. Following the sale, the chief operating officer now owns 111,998 shares of the company’s stock, valued at $8,697,764.68. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Andrew Hykes also recently made the following trade(s):

  • On Thursday, October 20th, Andrew Hykes sold 9,000 shares of Inari Medical stock. The shares were sold at an average price of $72.33, for a total value of $650,970.00.
  • On Tuesday, September 6th, Andrew Hykes sold 5,000 shares of Inari Medical stock. The shares were sold at an average price of $70.00, for a total value of $350,000.00.

Inari Medical Price Performance

Shares of NARI opened at $75.75 on Friday. The stock has a market capitalization of $4.06 billion, a price-to-earnings ratio of -180.36 and a beta of 1.21. Inari Medical, Inc. has a 1 year low of $50.50 and a 1 year high of $100.00. The business’s 50 day simple moving average is $73.75 and its 200-day simple moving average is $71.43.

Analyst Upgrades and Downgrades

NARI has been the subject of a number of recent research reports. Canaccord Genuity Group boosted their price objective on Inari Medical from $92.00 to $94.00 and gave the company a “buy” rating in a research note on Friday, September 16th. Wells Fargo & Company cut their price objective on Inari Medical from $125.00 to $105.00 in a research note on Thursday, November 3rd. Canaccord Genuity Group boosted their price objective on Inari Medical from $92.00 to $94.00 and gave the company a “buy” rating in a research note on Friday, September 16th. Berenberg Bank began coverage on Inari Medical in a research note on Thursday, September 29th. They set a “buy” rating and a $85.00 price objective for the company. Finally, Jefferies Financial Group began coverage on Inari Medical in a report on Wednesday, October 12th. They issued a “buy” rating and a $88.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $93.30.

Institutional Trading of Inari Medical

Hedge funds have recently modified their holdings of the company. Trustcore Financial Services LLC raised its holdings in shares of Inari Medical by 266.7% during the 1st quarter. Trustcore Financial Services LLC now owns 275 shares of the company’s stock worth $25,000 after acquiring an additional 200 shares in the last quarter. Parkside Financial Bank & Trust purchased a new stake in shares of Inari Medical during the 1st quarter worth approximately $25,000. Fifth Third Bancorp purchased a new stake in shares of Inari Medical during the 2nd quarter worth approximately $27,000. Canada Pension Plan Investment Board raised its holdings in Inari Medical by 40.9% during the 3rd quarter. Canada Pension Plan Investment Board now owns 689 shares of the company’s stock valued at $50,000 after buying an additional 200 shares during the period. Finally, DB Wealth Management Group LLC purchased a new stake in Inari Medical during the 1st quarter valued at $54,000. 84.11% of the stock is owned by hedge funds and other institutional investors.

About Inari Medical

(Get Rating)

Inari Medical, Inc, a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism.

Read More

Insider Buying and Selling by Quarter for Inari Medical (NASDAQ:NARI)

Receive News & Ratings for Inari Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inari Medical and related companies with MarketBeat.com's FREE daily email newsletter.